Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 14 bp deletion in exon 3.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-PSME1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PSME1 also known as PA28α (proteasome activator complex subunit 1) is a protein that functions as a regulatory component of the 20S proteasome. It has a molecular weight of approximately 28 kDa. This protein is expressed in various tissues with noticeable expression in immune-related tissues such as the spleen and thymus. PSME1 binds to proteasome core particles and modifies their activity by opening access to their catalytic core honing the degradation of ubiquitinated proteins.
Biological function summary
PSME1 modulates protein degradation processes and participates as a component of the immunoproteasome. The immunoproteasome is a complex that processes peptides for presentation on MHC class I molecules vital for immune response. This involvement transforms PSME1 into an important player in antigen processing and presentation influencing T-cell activation and immune surveillance. PSME1 affects immune system adaptability and efficiency impacting infection response and immune regulation.
Pathways
PSME1 is a significant participant in the ubiquitin-proteasome system and the MHC class I antigen processing pathway. It directly interacts with other proteasome components like the catalytic 20S core and the 11S regulator. The interplay with these proteins steers the precision and output of antigenic peptides essential for T-cell mediated immune recognition. By influencing these pathways PSME1 links the protein degradation machinery to adaptive immunity.
PSME1 has connections to autoimmune diseases and cancers. Alterations in its function or expression can disrupt regular proteasome activity leading to improper immune responses such as in autoimmune pathologies like systemic lupus erythematosus. Furthermore PSME1's role in antigen processing intersects with other proteins such as TAP1 affecting immune evasion strategies seen in certain cancers. These interactions suggest that PSME1 is a contributor in both immune-related health issues and cancer progression.
